Press Releases

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that it has successfully completed recruitment of the Radspherin® RAD-18-002 clinical study. All patients enrolled in the study will be followed until disease progression in the abdominal cavity, or for 12 months after the administration of Radspherin® whichever comes first. The biodistribution and radiation dosimetry after administration of R

Ahead of the world’s largest pharma event – CPhI Worldwide taking place in Milan, Italy (9-11 November, 2021) – the third part of the CPhI Annual Report is released with key findings for biologics manufacturing, biotechs and CDMOs. CPhI experts – Dawn Ecker, Managing Director of bioTRAK Database Services at BDO and Fiona Barry, Editor at GlobalData PharmSource – look ahead to 2025 to predict the future demand for biologicals by volume, as well as the to

BioTek reMEDys, one of the nation’s largest specialty infusion pharmacies focused on rare diseases, has announced the addition of UPLIZNA to its specialty therapeutics portfolio to provide treatment to a broader patient population and further expand upon its diverse pharmaceutical product offering. By adding UPLIZNA to its extensive portfolio of life-saving specialty therapies, BioTek reMEDys is furthering its commitment to respond to the needs of and requests of patients and

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari®, the Company's prescription L-glutamine oral powder for the treatment of sickle cell disease. Specifically, Asembia will provide a single point of contact for benefits investigation, financial an

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced or refractory solid tumors in a clinical trial of ALK-1 antibody (GT90001) in combination with KN046 on November 2 in Taiwan, China. This study (NCT04984668) is a two-stage, multicenter, open-label, phase Ib/II clinical trial to evaluate the safety, tolerability,

Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support a multi-center Phase 1b/2, randomized, double-blind, placebo-controlled trial assessing the safety and microbiological activity of a single dose of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aerugi

Family cord blood bank Cryoviva Singapore is pleased to announce that it has now been accredited by the Association of the Advancement of Blood & Biotherapies (AABB), formerly known as the American Association of Blood Banks, for both cord blood and somatic cells' banking services. Cryoviva is the first family cord blood bank in Singapore to get accredited by AABB for Somatic Cells' processing, storage, and distribution. The company had already been accredited by AABB pr

Synthekine Inc., an engineered cytokine therapeutics company, today announced it has entered into a worldwide research collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The collaboration will leverage Synthekine’s proprietary surrogate cytokine agonist platform to discover, develop, and commercialize novel cytokine therapeutics. “At Synthekine, we are focused on advancing cytokine science through three protein engineering

NoviSystems Inc., a company that empowers data-driven decisionmaking, has commercially launched Fusion Analytics for Quality Systems, an analytics solution for improving operational performance at pharmaceutical and biopharmaceutical manufacturing facilities in the new era of individualized medicine. "With the emergence of cell/gene therapy and individualized treatments, Fusion Analytics for Quality Systems is even more essential as bio/pharma manufacturers deal with increasing

CPhI & P-MEC India – organised by Informa Markets – is set to welcome attendees and exhibitors from around the world, both online and in-person, as new CPhI analysis points to sustained pharma growth in India, with an improving outlook for finished dosage, API and biologics. The India-specific findings of the CPhI Annual Report survey[1], conducted among 350 executives, point to a significant jump in the country’s global reputation with India widely perceived t